HitGen is focusing our innovative ability on discovering novel therapies that will make a real difference to patients with cancer or Inflammatory diseases. We have developed a broad and deep pipeline of both wholly owned and partnered therapeutics candidates. Our pipeline includes both small molecule and nucleic acid drug drugs.
Class I/IIb selective HDAC inhibitor, capsule
Class I/IIb selective HDAC inhibitor, capsule
2nd generation NTRK/ROS1 inhibitor, tablet
2nd generation STING agonist, iv
Menin-MLL, tablet
PROTAC
Small molecule inhibitor for IL-17a, po
ROCK2 inhibitor,eye drop
HitGen Inc.
Building C2, NO.8, Huigu 1st East Road
Tianfu International Bio-Town,
Shuangliu District, Chengdu City,
Sichuan Province,P.R. China
Tel : +86-28-8519-7385
HitGen Pharmaceuticals Inc.(US Subsidiary)
Tel : +1-(508)-840-9646
Vernalis (R&D) Limited (UK Subsidiary)
Granta Park,Great Abington
Cambridge,CB21 6GB
United Kingdom
Tel : +44(0)1223-895555
川公网安备 51012202000492号
We use cookies to provide a better web experience.
By using our site, you acknowledge our use of cookies and please read our Cookie Notice for
More information
